Voyager Therapeutics (NASDAQ:VYGR – Get Free Report) and Protara Therapeutics (NASDAQ:TARA – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk and institutional ownership.
Risk and Volatility
Voyager Therapeutics has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500. Comparatively, Protara Therapeutics has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500.
Analyst Ratings
This is a summary of recent recommendations for Voyager Therapeutics and Protara Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Voyager Therapeutics | 0 | 1 | 2 | 0 | 2.67 |
| Protara Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
Institutional & Insider Ownership
58.8% of Voyager Therapeutics shares are owned by institutional investors. Comparatively, 46.4% of Protara Therapeutics shares are owned by institutional investors. 4.7% of Voyager Therapeutics shares are owned by insiders. Comparatively, 18.4% of Protara Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares Voyager Therapeutics and Protara Therapeutics’ top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Voyager Therapeutics | $194.87 million | 1.71 | -$46.41 million | $2.27 | 3.35 |
| Protara Therapeutics | N/A | N/A | -$65.95 million | ($5.94) | -0.29 |
Voyager Therapeutics has higher revenue and earnings than Protara Therapeutics. Protara Therapeutics is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Voyager Therapeutics and Protara Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Voyager Therapeutics | N/A | 69.09% | 38.58% |
| Protara Therapeutics | N/A | -35.59% | -32.35% |
Summary
Voyager Therapeutics beats Protara Therapeutics on 8 of the 12 factors compared between the two stocks.
About Voyager Therapeutics
Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of Alzheimer's disease. It also develops VY-FXN01 to treat Friedreich's ataxia; superoxide dismutase 1 gene silencing program for the treatment of amyotrophic lateral sclerosis; and GBA1 gene replacement program to treat Parkinson's disease. In addition, the company develops research program for the treatment of Huntington's disease. It has collaboration and license agreements with Neurocrine Biosciences, Inc.; Pfizer Inc.; and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
About Protara Therapeutics
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. The company is headquartered in New York, New York.
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
